HR and bone metastasis: In patients with bone metastasis, a bulk of them were HR+/HER2−, accounting for 44.7%, and those with HR-/HER2+ accounts for a mere 4.5%; In patients with lung metastasis, the percentage were HR+/HER2− (16.2%), HR+/HER2+ (4.9%), HR-/HER2+ (3.2%), HR-/HER2− (6.0%); In patients with liver metastasis, the percentage were HR+/HER2− (12.0%), HR+/HER2+ (6.0%), HR-/HER2+ (4.0%), HR-/HER2− (4.2%).